Published in Lab Law Weekly, September 7th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Oncolytics Biotech Inc..
Report 1: Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced positive results from its U.S. Phase I clinical trial examining the systemic administration of REOLYSIN(R) in patients with advanced cancers. The results indicate that REOLYSIN(R) can be delivered systemically to patients with advanced and metastatic cancers and cause anti-tumour activity.
"REOLYSIN(R) administered as a one-hour infusion on a monthly...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly